Reports and Briefs on Hematology in Europe

Published within

« | 1 | » »|

Type Product title / description Pub Price
Report
Report

Myelodysplastic Syndrome: An Underserved Population Offers Commercial Opportunity

SuperGen/MGI Pharma's Dacogen and Celgene's Revlimid are in pre-registration for treatment of myelodysplastic syndrome (MDS). However, a significant proportion of the MDS population will be left underserved by pharmacotherapy.

Published By Datamonitor
18 Oct 2005 $1900
Buy
Report
Report

Stakeholder Insight: Acute Leukemias - Reaching the limits of cytotoxic chemotherapy

Primary research-based analysis of the chronic leukemias market. Includes patient segmentation, treatment trends, prescribing influences and brand perception.

Published By Datamonitor
08 Oct 2009 $15200
Buy
Report
Report

Stakeholder Insight: Non-Hodgkin's Lymphomas Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL)

Primary research-based analysis of the non-Hodgkin's lymphomas market, including epidemiology, patient segmentation, and treatment data. Separate coverage of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).

Published By Datamonitor
17 Dec 2009 $15200
Buy
Report
Report

Pipeline Insight: Leukemias - Underserved patient populations offer potential for market growth

Overview of the current leukemias pipeline, including in-depth analysis of late-phase products for the four main leukemia subtypes, clinical trial data, sales forecasts through to 2019 and key opinion leader insight.

Published By Datamonitor
29 Mar 2010 $11400
Buy
Report
Report

Case Study: Personalized Cancer Therapy - Anticipated competition threatens to dampen commercial potential of new approvals

Overview of targeted cancer therapies and biomarkers, with in-depth analysis of drug and companion diagnostic development, commercial potential, role of regulatory authorities in the seven major markets and key pipeline personalized cancer therapies.

Published By Datamonitor
16 Jul 2012 $1900
Buy

« | 1 | » »|

No help is available.